Sangamo, in Chapter 11, agrees to sell ST-920 Fabry gene therapy assets to PTC for USD 111 million upfront
SGMO•Sangamo agrees to sell ST-920 Fabry gene therapy assets to PTC
Sangamo entered an asset purchase agreement to sell ST-920 Fabry disease gene therapy assets to PTC in a Chapter 11 Section 363 process.
Deal value is set at USD 111 million cash at closing, contingent payments of up to USD 100 million are tied to FDA accelerated and full approval milestones.
The transaction requires a Delaware bankruptcy court sale order; a hearing is scheduled for Sept. 10, 2026.
The outside closing date is Oct. 15, 2026, subject to specified exceptions and termination rights.
